Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes

Source Citation Tang H, Li D, Zhang J, et al. Sodium–glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017 Feb 27 [Epub ahead of print]. 28240446